Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Always use with caution
Full Formulation Ownership Transfer Upon project completion for custom-developed formulas: Client-exclusive ownership of formulation IP and technical documentation No internal reuse of client-specific formulas Handover of specs, SOPs, and COA references as contracted Batch history / manufacturing record access per agreement Optional Exclusivity Structures Regional / category (e.g., liposomal glutathione in a defined channel) / time-bound / volume-threshold, contract-defined
mTORC1 inhibition in cancer cells protects from glutaminolysis-mediated apoptosis during nutrient limitation
order: 200 pieces Foshan Meixin Biotechnology Co., Ltd
The statements made within the website have not been evaluated by the USA Food and Drug Administration
The big reveal on the Going Public TV show: The PRUVN study's findings, including the journey of Max International partnering with PRUVN for this human trial, will be unveiled on the Going Public TV show in May 2024
US$ 23.57
US$ 24.71
:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)
US$ 26.48
US$ 28.51
